Serving To Educate Primary Care Clinicians On Metabolic Issues
Evidence Based Medicine Header 1
Medical Education Header 2
Peer-to-peer Exchange Header 3
Metabolic Diseases Header 4
News: Prescriber's Letter November 2015

You'll hear cautious optimism about cardiovascular benefits with the SGLT2 inhibitor, Jardiance (empagliflozin)
   Until now, metformin seemed to be the only diabetes med linked to a reduction in cardiovascular events in patients with type 2 diabetes. 
   But new evidence suggests that Jardiance also reduces CV risk. 
   This is a surprise...and has researchers perplexed about the mechanism of CV benefit. But it's likely NOT due to A1C lowering. 
   Don't be too quick to jump on the Jardiance bandwagon. 
   Jardiance prevents CV death in one in 45 type 2 diabetes patients over 3 years...and overall mortality in one in 39 patients. 
   Plus patients seem to have a lower risk of sudden cardiac death or worsening heart failure...but NOT fewer MIs or strokes. 
   And any CV benefit is ONLY in type 2s who have CV disease when ADDED to optimal therapy (metformin, statin, ACEI, etc). 
   Stick with metformin first-line for most type 2s. 
   And continue to focus on other proven strategies for reducing CV risk in diabetes...controlling blood pressure, using a statin, etc. 

If you would like to access this month's full article on Jardiance from Prescriber's letter, please click here

Prescriber's Letter offers PCMG Members a 10% discount at two subscription levels:

The Gold Subscription is $129  and includes CME

The Platinum Subscription is $189 and provides enhanced CME and Live Webinar access 

Enter Discount Code PCMG15 when ordering either subscription HERE